

# Évaluation et prise en charge de la COVID Longue en physiothérapie

**Simon Décary, pht, PhD**

Professeur adjoint

Université de Sherbrooke



Laboratoire sur la santé musculosquelettique en soins primaires

**Association québécoise de la physiothérapie**

**2 Décembre 2021**



UNIVERSITÉ DE  
SHERBROOKE



# Quick evidence update about Long COVID.

# A clinical case definition of post COVID-19 condition by a Delphi consensus

6 October 2021



Post COVID-19 condition occurs in individuals with a **history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis.** Common symptoms include **fatigue, shortness of breath, cognitive dysfunction** but also others (see **Table 3** and **Annex 2**) which generally have an **impact on everyday functioning.** Symptoms may be **new onset**, following initial recovery from an acute COVID-19 episode, or **persist** from the initial illness. Symptoms may also **fluctuate** or **relapse** over time. A separate definition may be applicable for children.

# Prevalence of Long COVID

Home

Business, industry  
and trade

Economy

Employment and  
labour market

People, population  
and community

Taking part in a  
survey?

Search for a keyword(s) or time series ID



[Home](#) > [People, population and community](#) > [Health and social care](#) > [Coronavirus \(COVID-19\)](#) >

Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK

## Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK : 2 December 2021

Estimates of the prevalence of self-reported long COVID and associated activity limitation, using UK Coronavirus (COVID-19) Infection Survey data.

This is the latest release. [View previous releases](#)

Contact:

[Daniel Ayoubkhani](#), [Sasha King](#) and  
[Matt Bosworth](#)

Release date:

2 December 2021

Next release:

6 January 2022

1.2 million people with symptoms >4 weeks 1.9% UK population

◆ Of these, 862k have symptoms >12 weeks: 81%

◆ 439k symptoms >12 months: 36%

◆ 64% day to day activities impacted

◆ 19% severely limited

**The most conservative estimates indicate that 10% of all cases will develop persistent symptoms at 12 weeks.**

- Among a sample of over 20,000 study participants who tested positive for COVID-19 between 26 April 2020 and 6 March 2021, 13.7% continued to experience symptoms for at least 12 weeks. This was eight times higher than in a control group of participants who are unlikely to have had COVID-19, suggesting that the prevalence of ongoing symptoms following coronavirus infection is higher than in the general population.

# Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review

## Authors:

Chen Chen, MA<sup>1,\*</sup>, Spencer R. Hauptert, BS<sup>1,\*</sup>, Lauren Zimmermann, BSc<sup>1,2</sup>, Xu Shi, PhD<sup>1</sup>, Lars G. Fritsche, PhD<sup>1,3,4</sup>, Bhramar Mukherjee, PhD<sup>1,2,3,4,5</sup>

## Affiliations:

<sup>1</sup> Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA

<sup>2</sup> Center for Precision Health Data Science, University of Michigan, Ann Arbor, MI 48109, USA

<sup>3</sup> Rogel Cancer Center, University of Michigan Medicine, Ann Arbor, MI 48109, USA

<sup>4</sup> Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA

<sup>5</sup> Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA

\* Equal contributions

## Correspondence to:

Bhramar Mukherjee, PhD  
Department of Biostatistics  
University of Michigan School of Public Health  
1415 Washington Heights  
Ann Arbor, MI 48109.  
Email: [bhramar@umich.edu](mailto:bhramar@umich.edu)

## Results


Global estimated pooled PASC prevalence derived from the estimates presented in 29 studies was 0.43 (95% confidence interval [CI]: 0.35, 0.63), with a higher pooled PASC prevalence estimate of 0.57 (95% CI: 0.45, 0.68), among those hospitalized during the acute phase of infection. Females were estimated to have higher pooled PASC prevalence than males (0.49 [95% CI: 0.35, 0.63] versus 0.37 [95% CI: 0.24, 0.51], respectively). Regional pooled PASC prevalence estimates in descending order were 0.49 (95% CI: 0.21, 0.42) for Asia, 0.44 (95% CI: 0.30, 0.59) for Europe, and 0.30 (95% CI: 0.32, 0.66) for North America. Global pooled PASC prevalence for 30, 60, 90, and 120 days after index test positive date were estimated to be 0.36 (95% CI: 0.25, 0.48), 0.24 (95% CI: 0.13, 0.39), 0.29 (95% CI: 0.12, 0.57) and 0.51 (95% CI: 0.42, 0.59), respectively. Among commonly reported PASC symptoms, fatigue and dyspnea were reported most frequently, with a prevalence of 0.23 (95% CI: 0.13, 0.38) and 0.13 (95% CI: 0.09, 0.19), respectively.

# 100M de cas de COVID Longue dans le monde...

# Prognosis

40% of people with Long COVID will have persistent symptoms and impact **12 months** after the infection.

ONS, 2021



Whitaker, M. et al, [preprint 2021].  
Persistent symptoms following  
SARS-CoV-2 infection in a random  
community sample of 508,707



ELSEVIER

Contents lists available at [ScienceDirect](#)

### EClinicalMedicine

journal homepage: <https://www.journals.elsevier.com/eclinicalmedicine>



Research Paper

## Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Hannah E. Davis<sup>a,1</sup>, Gina S. Assaf<sup>a,1</sup>, Lisa McCorkell<sup>a,1</sup>, Hannah Wei<sup>a,1</sup>, Ryan J. Low<sup>a,b,1</sup>, Yochai Re'em<sup>a,c,1</sup>, Signe Redfield<sup>a</sup>, Jared P. Austin<sup>a,d</sup>, Athena Akrami<sup>a,b,1,\*</sup>

scientific reports


OPEN

# More than 50 long-term effects of COVID-19: a systematic review and meta-analysis

Sandra Lopez-Leon<sup>1</sup>, Talia Wegman-Ostrosky<sup>2</sup>, Carol Perelman<sup>3</sup>, Rosalinda Sepulveda<sup>4</sup>, Paulina A. Rebolledo<sup>5,6</sup>, Angelica Cuapio<sup>7</sup> & Sonia Villapol<sup>8,9</sup>

Check for updates

## Long-term effects of COVID-19





## Early symptom clusters


64.6	16.2	Appetite loss
61.5	13.4	Severe fatigue
68.9	22.8	Shortness of breath
59.3	15.1	Chills
45.5	15.9	Heavy arms/legs
64.0	22.8	Tight chest
53.5	13.8	Difficulty sleeping
38.2	11.8	Dizziness
30.4	15.6	Blocked nose
28.3	16.0	Runny nose
21.4	10.1	Diarrhoea
34.7	9.7	Chest pain
20.1	6.3	Nausea/vomiting
32.5	11.1	Hoarse voice
22.2	8.7	Sore eyes
18.4	6.3	Abdominal pain / belly ache
22.2	10.9	Sneezing
12.6	3.7	Numbness/tingling
6.4	2.8	Red, itchy areas on skin
1.4	0.4	Sudden swelling to face or lips
1.7	1.0	Purple sores/blisters on feet
41.3	26.9	Loss or change of sense of taste
36.3	25.6	Loss or change of sense of smell
73.3	40.1	New persistent cough
65.9	32.6	Sore throat
78.5	56.9	Tiredness
84.5	38.2	Muscle aches
81.0	39.7	Headache
81.5	32.0	Fever

Cluster A1	Cluster A2
n=18,331	n=34,978

**A1**   **A2**



Symptom onset → 12 weeks after symptom onset

### A1


**n=18,331**

High prevalence of all symptoms, especially muscle aches, head-ache, fever, appetite loss, cough, shortness of breath, and chills, at time of infection

### A2

**n=34,978**

Lower prevalence of all symptoms, especially flu-like and respiratory, at time of infection



### No symptoms

**n=33,069**

No persistent symptoms 12 weeks after symptom onset

### L1: tiredness

**n=15,799**

High prevalence of tiredness

### L2: respiratory

**n=4,441**

High prevalence of respiratory symptoms

## Symptom clusters at 12 weeks

7.1	9.0	Appetite loss
6.7	12.9	Severe fatigue
11.1	85.8	Shortness of breath
3.0	4.5	Chills
7.7	12.5	Heavy arms/legs
3.1	61.2	Tight chest
19.8	21.0	Difficulty sleeping
7.5	12.3	Dizziness
7.7	8.5	Blocked nose
7.2	6.0	Runny nose
3.6	3.7	Diarrhoea
3.0	20.9	Chest pain
2.0	3.2	Nausea/vomiting
5.0	9.1	Hoarse voice
7.5	9.1	Sore eyes
3.7	6.0	Abdominal pain / belly ache
5.7	5.0	Sneezing
5.1	7.9	Numbness/tingling
3.1	3.4	Red, itchy areas on skin
0.2	0.5	Sudden swelling to face or lips
0.8	0.9	Purple sores/blisters on feet
12.5	9.3	Loss or change of sense of taste
15.5	9.8	Loss or change of sense of smell
9.6	16.6	New persistent cough
7.7	8.8	Sore throat
50.8	29.1	Tiredness
18.7	23.7	Muscle aches
13.9	15.3	Headache
2.9	4.8	Fever

Cluster L1	Cluster L2
n=15,799	n=4,441

**L1**   **L2**

Whitaker, M. et al, [preprint 2021]. Persiste SARS-CoV-2 infection in a random commu people



Centre hospitalier universitaire de Sherbrooke



UNIVERSITÉ DE SHERBROOKE

Faculté de médecine et des sciences de la santé

RESEARCH CENTER

**Supplementary Table 1. FACIT-F scores in a range of other populations for comparison with long COVID**

<b>Disease or Clinical condition</b>	<b>FACIT-F*</b>	<b>n</b>	<b>Age*</b>	<b>%Female*</b>	<b>Study</b>
Long COVID	18 ± 10	213	Table 1	85	-
General population	44 ± 9	1010	46 ± 17	52	[11]
Cancer & anemia	24 ± 13	2292	63 ± 13	65	[11]
Chronic cancer-related fatigue	27 ± 7	51	54 ± 11	65	[12]
Human immunodeficiency virus	34 ± 13	51	40 ± 7	12	[13]
Rheumatoid arthritis	29 ± 11	631	56 <sup>‡</sup>	79	[14]
Psoriatic arthritis	36 ± 12	135	52 ± 13	42	[15]
Iron deficiency anemia	24 ± 12	608	45 ± 14	89	[16]
Chronic obstructive pulmonary disease	42 ± 9	564	68 ± 10	68	[17]
Parkinson's disease	34 ± 10	118	64 ± 10	46	[18]
Chronic immune thrombocytopenia	36 ± 12	207	50 <sup>‡</sup>	67	[19]
Stroke	38 ± 10	51	63 ± 14	51	[13]

\*Values have been rounded for presentation. <sup>‡</sup>=median

## **Chronic fatigue and post-exertional malaise in people living with long COVID**


 Rosie Twomey, Jessica DeMars, Kelli Franklin,  S. Nicole Culos-Reed,  Jason Weatherald,  James G. Wrightson

**doi:** <https://doi.org/10.1101/2021.06.11.21258564>



**RESEARCH CENTER**





## Chronic fatigue and post-exertional malaise in people living with long COVID

Rosie Twomey, Jessica DeMars, Kelli Franklin, S. Nicole Culos-Reed, Jason Weatherald, James G. Wrightson

doi: <https://doi.org/10.1101/2021.06.11.21258564>





RESEARCH CENTER



# Meanwhile in Canada...

- Despite strong vaccination efforts, 1.64M cases, 27K deaths, for a 38M population
- We are currently in our 4<sup>th</sup> wave of the pandemic
- Challenges for Long COVID care organization in Canada:
  - 13 independent provinces and territories.
  - Population spread across a large geography, including northern territories.



# The Public Health Agency of Canada recognized the condition on July 7th 2021.

[www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html](http://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms/post-covid-19-condition.html)



Government  
of Canada

Gouvernement  
du Canada

Search Canada.ca



MENU ▾

[Canada.ca](#) > [Coronavirus disease \(COVID-19\)](#) > [Symptoms and treatment](#)

## Post COVID-19 condition

### On this page

- [About](#)
- [Symptoms](#)
- [Mental health](#)
- [Prevention, diagnosis and treatment](#)
- [What Canada's doing](#)



Centre hospitalier  
universitaire  
de Sherbrooke



UNIVERSITÉ DE  
SHERBROOKE

Faculté de médecine  
et des sciences de la santé

RESEARCH CENTER

**Humility:**  
**Primary care rehabilitation is safe, but it takes  
more than 3 months to recover.**

---

# [ EDITORIAL ]

---


**SIMON DÉCARY, PT, PhD<sup>1</sup> • ISABELLE GABOURY, PhD<sup>2</sup> • SABRINA POIRIER<sup>3</sup> • CHRISTIANE GARCIA<sup>4</sup>  
SCOTT SIMPSON, BA, CWC<sup>5</sup> • MICHELLE BULL, PhD<sup>6</sup> • DARREN BROWN, MSc, MRes<sup>7</sup> • FRÉDÉRIQUE DAIGLE, MSc<sup>1</sup>**

# Humility and Acceptance: Working Within Our Limits With Long COVID and Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome





**STOP** trying to push your limits. Overexertion may be detrimental to your recovery.



**REST** is your most important management strategy. Do not wait until you feel symptoms to rest.



**PACE** your daily physical and cognitive activities. This is a safe approach to navigate triggers of symptoms.

**FIGURE.** The “Stop. Rest. Pace” approach to safely manage physical and cognitive activities while recovering from long COVID.





### About this Attention Score

In the top 5% of all research outputs scored by Altmetric

One of the highest-scoring outputs from this source (#4 of 2,132)

High Attention Score compared to outputs of the same age (99th percentile)

High Attention Score compared to outputs of the same age and source (95th percentile)

LESS...

### Mentioned by

- 1 news outlet
- 3 blogs
- 877 tweeters
- 12 Facebook pages
- 1 Redditor

### Citations

- 3 Dimensions

### Readers on

- 61 Mendeley

What is this page?

### SUMMARY

- News
- Blogs
- Twitter
- Facebook
- Reddit
- Dimensions citations

**Title** Humility and Acceptance: Working Within Our Limits With Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

**Published in** Journal of Orthopaedic & Sports Physical Therapy, May 2021

**DOI** 10.2519/jospt.2021.0106 [↗](#)

**Pubmed ID** 33930983 [↗](#)

**Authors** Simon Décary, Isabelle Gaboury, Sabrina Poirier, Christiane Garcia, Scott Simpson, Michelle Bull... [\[show\]](#)

**Abstract** The term long COVID was coined by patients to describe the long-term consequences of COVID-19. One... [\[show\]](#)

[↗ View on publisher site](#)


[✉ Alert me about new mentions](#)

### TWITTER DEMOGRAPHICS

### MENDELEY READERS

### ATTENTION SCORE IN CONTEXT

The data shown below were collected from the profiles of **877** tweeters who shared this research output. [Click here to find out more about how the information was compiled.](#)



### Geographical breakdown

Country	Count	As %
United Kingdom	115	13%
United States	83	9%
Canada	75	9%
Spain	30	3%
Japan	24	3%
Germany	22	3%
Australia	15	2%
France	14	2%
Sweden	11	1%
Other	68	8%
Unknown	420	48%

### Demographic breakdown

Type	Count	As %
Members of the public	764	87%
Practitioners (doctors, other healthcare professionals)	53	6%
Scientists	52	6%
Science communicators (journalists, bloggers, editors)	7	<1%
Unknown	1	<1%

# The TELEPORT clinical study

## ▶ AIMS

- ❖ Establish the safety of a primary care interprofessional rehabilitation service for people living with Long COVID.
- ❖ Describe the effect on recovery of quality of life, pulmonary symptoms and fatigue.

## ▶ METHODS

- ❖ **Study design:** A nonrandomized pre-post intervention study. All participants were assessed at initial assessment (pre intervention), at 4, 8 and 12 weeks (post intervention). All assessments were conducted by a trained and blinded assessor.
- ❖ **Population:** We recruited 34 people living with Long COVID from the community, defined as having persistent symptoms at least 4 weeks following a suspected or confirmed acute COVID-19.
- ❖ **Intervention:** Participants received a 12-week primary care interprofessional rehabilitation intervention including 8 physiotherapy sessions (e.g. breathing exercises, activity monitoring) and 6 occupational therapy sessions (e.g. energy management, return to work). In total, participants received up to 14 hours of rehabilitation services. Rehabilitation was based on our *Stop. Rest. Pace* safe approach to prevent relapses while recovering from a post-viral illness.
- ❖ **Outcomes:** **1-** Health-related quality of life (EuroQoL-5D-5L, Visual Analog Scale, score 0 to 100); **2-** Pulmonary symptoms (COPD Assessment Test, 8-item, score 0 to 40). **3-** Fatigue (Chalder Fatigue Scale, 11-item, score 0 to 33) and **4-** Post-exertional malaise (DePaul Symptom Questionnaire, 5-item, score positive/negative based on frequency and intensity of symptoms).
- ❖ **Data analysis.** Descriptive statistics. Within subject pre-post comparison between initial assessment and 12-week follow-up.

## ► RESULTS

- Data collection from February 1<sup>st</sup> 2021 to July 30<sup>th</sup> 2021.
- 49 patients assessed with a standardized form based on the ICF: 70% inclusion rate.
- Participants had an average of 8 symptoms, commonly fatigue (100%), breathlessness (91%) and limitation in work and daily living activities (88%).
- 34 began the project, 30 completed it. **4 loss to follow-up, mainly for deterioration of medical condition.**

	Mean ± SD	N (%)
Age	45,0 ± 9,1	
Female gender		30 (88)
Days since COVID-19 infection	142,7 ± 94,3	
Participants requiring hospitalization		7 (21)
Participants with of at least one prior comorbidity		22 (65)
Body mass index	27,5±5,2	
Participants with household support		29 (85)
Participants with post-exertional malaise		34 (100)

**Table 1.** Participants' characteristics, n=34.

# DePaul Questionnaire

Symptoms	Frequency:	Severity:
	Throughout the <b>past 6 months</b> , <b>how often</b> have you had this symptom? For each symptom listed below, circle a number from:	Throughout the <b>past 6 months</b> , <b>how much</b> has this symptom bothered you? For each symptom listed below, circle a number from:
	<b>0 = none of the time</b> <b>1 = a little of the time</b> <b>2 = about half the time</b> <b>3 = most of the time</b> <b>4 = all of the time</b>	<b>0 = symptom not present</b> <b>1 = mild</b> <b>2 = moderate</b> <b>3 = severe</b> <b>4 = very severe</b>
1. Dead, heavy feeling after starting to exercise	0 1 2 3 4	0 1 2 3 4
2. Next day soreness or fatigue after non-strenuous, everyday activities	0 1 2 3 4	0 1 2 3 4
3. Mentally tired after the slightest effort	0 1 2 3 4	0 1 2 3 4
4. Minimum exercise makes you physically tired	0 1 2 3 4	0 1 2 3 4
5. Physically drained or sick after mild activity	0 1 2 3 4	0 1 2 3 4

## Supplementary Questions

6. If you were to become exhausted after actively participating in extracurricular activities, sports, or outings with friends, would you recover within an hour or two after the activity ended?	Yes	No				
7. Do you experience a worsening of your <b>fatigue/energy related illness</b> after engaging in minimal physical effort?	Yes	No				
8. Do you experience a worsening of your <b>fatigue/energy related illness</b> after engaging in mental effort?	Yes	No				
9. If you feel worse after activities, how long does this last?	≤1 h	2-3 h	4-10 h	11-13 h	14-23 h	≥ 24 h
10. If you do not exercise, is it because exercise makes your symptoms worse?	Yes	No				



Centre hospitalier  
universitaire  
de Sherbrooke




UNIVERSITÉ DE  
SHERBROOKE

Faculté de médecine  
et des sciences de la santé

RESEARCH CENTER

# DePaul Questionnaire



**Item 1.** Dead, heavy feeling after starting to exercise

**Item 2.** Next day soreness or fatigue after non-strenuous, everyday activities

**Item 3.** Mentally tired after the slightest effort

**Item 4.** Minimum exercise makes your physically tired

**Item 5.** Physically drained or sick after mild activity

**Figure 1.** Percentage of participants scoring positive (frequency and intensity) for each item to DePaul Questionnaire between T1 and T6. Lower percentage positive indicates less severity and frequency of post-exertional malaise symptoms.

	T1	T2	T3	T4	T5	T6
Participant 1	Positif	Positif	Négatif	Positif	Positif	Négatif
Participant 2	Positif	Positif	Positif	Négatif	Positif	Positif
Participant 4	Positif	Positif	Positif	Positif	Positif	Positif
Participant 5	Positif	Négatif	Négatif	Négatif	Négatif	Négatif
Participant 7	Positif	Positif	Négatif	Négatif	Positif	Positif
Participant 9	Positif	Positif	Négatif	Négatif	Négatif	Négatif
Participant 10	Positif	Positif	Positif	Positif	Positif	Positif
Participant 17	Positif	Positif	Positif	Positif	Négatif	Négatif
Participant 18	Positif	Positif	Positif	Positif	Positif	Positif
Participant 20	Positif	Positif	Positif	Positif	Positif	Positif
Participant 21	Positif	Positif	Positif	Positif	Positif	Positif
Participant 22	Positif	Positif	Positif	Positif	Positif	Positif
Participant 23	Positif	Positif	Positif	Positif	Négatif	Négatif
Participant 25	Positif	Positif	Positif	Négatif	Négatif	Négatif
Participant 26	Positif	Positif	Positif	Positif	Positif	Négatif
Participant 27	Positif	Positif	Positif	Positif	Positif	Positif
Participant 29	Positif	Positif	Positif	Positif	Positif	Positif
Participant 31	Positif	Positif	Positif	Positif	Positif	Positif
Participant 32	Positif	Positif	Positif	Positif	Positif	Négatif
Participant 33	Positif	Positif	Positif	Positif	Positif	Positif
Participant 34	Positif	Positif	Positif	Positif	Positif	Positif
Participant 37	Positif	Positif	Positif	Positif	Positif	Négatif
Participant 39	Positif	Positif	Positif	Positif	Positif	Positif
Participant 41	Positif	Positif	Négatif	Positif	Positif	Positif
Participant 42	Positif	Positif	Positif	Positif	Positif	Négatif
Participant 43	Positif	Positif	Positif	Négatif	Positif	Positif
Participant 44	Positif	Positif	Positif	Positif	Positif	Positif
Participant 45	Positif	Positif	Positif	Positif	Positif	Positif
Participant 46	Positif	Positif	Positif	Positif	Positif	Négatif
Participant 49	Positif	Positif	Positif	Positif	Positif	Positif

## Interpretation:

- One « negative » = improvement
  - 11/34 participants improved
- Two « negative » = improvement
  - 5/34 participants improved



Centre hospitalier  
universitaire  
de Sherbrooke



UNIVERSITÉ DE  
SHERBROOKE

Faculté de médecine  
et des sciences de la santé


RESEARCH CENTER

	<b>Pre intervention Mean ± SD</b>	<b>Post intervention Mean ± SD</b>	<b>P-value</b>
EQ-VAS	46.7 ± 16.4	52.8 ± 16.3	P=0.51
COPD Assessment Test	19.7 ± 7.7	15.3 ± 8,5	P=0.19
Chalder Fatigue Scale	26.0 ± 4.4	24.5 ± 6.4	P=0.42

**Table 2.** Primary outcome measures pre and post intervention. EQ-VAS: Euro-QoL Visual Analog Scale, score 0 to 100, higher score indicates better quality of life. COPD Assessment Test, score 0 to 40, lower score indicates better pulmonary health. Chalder Fatigue Scale, score 0 to 33, lower score indicates less fatigue.

# Return to work

- Stopped working because of a COVID-19 infection: 30 participants/34
- Attempts to return to work: 16 participants/34
- Unable to return to work (partial or fully): 23 participants/34





## ► CONCLUSION

- ❖ Although our rehabilitation approach did not triggered relapses, post-exertional malaise, breathlessness and fatigue still impacted quality of life even after 12 weeks of pacing education and rehabilitation by physiotherapists and occupational therapists.
- ❖ Rehabilitation may reduce intensity and frequency of relapses.
- ❖ Only a third of participants were able to return to work at 12 weeks.
- ❖ A combination of medical and personalized rehabilitation approaches are required in primary care to help people with Long COVID to recover.

## ► PROPOSITIONS

- ❖ Increase follow-up duration to 6 to 12 months while reducing intensity of follow-up with same total exposure (e.g. one session every two weeks spread across 6 months).
- ❖ Develop specific interventions for return to work. Insurers have a massive role to play. This disease does not follow a traditional recovery trajectory.
- ❖ Always work with medical professional, medical relapses of comorbidities is extremely likely.
- ❖ This is a complex population, train local champion who will have at least 2 days per week of Long COVID in their caseload to develop expertise.
- ❖ Rehabilitation are key player for the initial assessment. Rehabilitation is way more than an exercise program.

# Knowledge mobilization in rehabilitation can change the world...



## Réponse de World Physiotherapy à la COVID-19

Document d'information 9

APPROCHES DE RÉADAPTATION SÛRES POUR  
LES PERSONNES VIVANT AVEC UN COVID LONG :  
ACTIVITÉ ET EXERCICE PHYSIQUE



About Resources Podcast Blog Our Work Peer Support Contact



# LONG COVID PHYSIO

Our website is for everybody living with Long COVID  
and anyone wanting to learn more



Продължителният КОВИД-19 се определя като наличие на признаци и симптоми, които се развиват по време или след инфекция, съответстваща на КОВИД-19, които продължават 12 седмици или повече.  
За остър КОВИД-19 се приема до 4-та седмица и за продължаващ КОВИД-19 от 4-та до 12-та седмица след началото на болестта.



Колко чест е продължителният КОВИД-19?  
1 от 10 случая проявяват симптоми за 12 седмици или повече



Повечето хора, живеещи с болестта, са били здрави и в добра форма.



Деца проявяват симптоми на продължителен КОВИД подобни на тези при възрастните и с приблизително същата честота.

Продължителният КОВИД засяга хора, които са били хоспитализирани с остър КОВИД-19 и тези, които са се възстановявали у дома. Лицата, които са преживели както лек, така и тежък КОВИД-19, също могат да продължат да имат симптоми или да развият продължителен КОВИД.

Продължителният КОВИД е мултисистемно заболяване с над 200 съобщени симптоми, проявяващи се в различни комбинации, които могат да варират както в предсказуеми, така и в непредсказуеми модели на обостряния и ремисии.

Най-чести симптоми след шестия месец:



силно изтощение (лесна умора)  
обостряне на симптомите след натоварване (ОСЧН)



проблеми с паметта и концентрацията

МИ:



задух




депресия и тревожност

# Acceptance: Opportunities for a new future.

# A Review of Care Models?

- Long COVID was recognized very early in Canada
- Our first post COVID clinics were set up as early as May 2020
- Alberta was also among the first province to create a task force to organize care models for Long COVID
- COVID-END received a first query on care models in April 2021
- Public Health Agency of Canada officially recognized Post COVID-19 Condition in July 2021



# Care Models for Long COVID

## A Rapid Systematic Review

**Date of Literature Search: 5/27/2021**

**Date of Submission: 6/18/2021**

**Prepared by:**

Simon Décary, PT, PhD  
Léa Langlois, MSc  
Annie LeBlanc, PhD

Michèle Dugas, MSc  
Becky Skidmore, PhD

Théo Stefan, MSc  
Anne Bhéreur, MD

**For and in close collaboration with:**

Alberta Health Services  
Stephanie Hastings, PhD  
Branden Manns, MD, MSc  
Lynora Saxinger, PhD

[https://sporevidencealliance.ca/wp-content/uploads/2021/06/Care-Models-for-Long-COVID\\_Full-Report\\_2021.06.18.pdf](https://sporevidencealliance.ca/wp-content/uploads/2021/06/Care-Models-for-Long-COVID_Full-Report_2021.06.18.pdf)

# Methods

- **Objective:** To provide the best-available evidence about care models for people living with Long COVID
- We performed a **rapid systematic review** following the Joanna Briggs Institute's Manual for Evidence Synthesis
- We systematically searched on May 27<sup>th</sup> 2021 seven electronic database: MEDLINE, Embase, Web of Science, COVID-END, L-OVE, CDRS and WHO Ovid
- Two independent reviewers screened title, abstract and full text
- We included studies reporting on 1 - people living with Long COVID and 2- a specific care model (i.e. structured clinic, care pathway).
- We extracted characteristic of studies, referral pathways, clinical settings of care model, staffing, care model components and reporting of the care model implementation.

## Eligibility Criteria

Our inclusion criteria (PICO) were as followed:


---

<b>Population:</b>	Persons living with Long COVID (children and adults) or healthcare professionals managing Long COVID. We included all definition of persistent symptoms of COVID-19 (e.g., post-COVID syndrome).
<b>Intervention:</b>	Care models (including pathways, trajectories, frameworks or structured clinics) to organise health care services for Long COVID.
<b>Comparator:</b>	Natural recovery, usual care models, inter-jurisdiction models comparison if available.
<b>Outcomes:</b>	Any outcomes or specifically system-level outcomes (e.g., cost, access, quadruple aim), patient-level outcomes (e.g., specific PROMS related to symptoms), clinician-level outcome (e.g., satisfaction with the care pathways).
<b>Study design:</b>	Any design.
<b>Settings:</b>	Any setting.

---

# Results

- We screened 2181 citations, read 65 full texts and included 12 international care models for Long COVID.
- Half of studies were from the United Kingdom.
- 7 out of 12 studies reported conceptual models without a description of implementation
- All but one model was designed for discharge and long-term follow-up of hospitalized patient and half for non-hospitalized
- A total of **30 healthcare professions** and medical specialities were proposed for staffing Long COVID services.
- **Principles (22):** multidisciplinary teams, integrated/coordination of care.
- **Components (10):** Standardized assessment, follow-up system and virtual care



# A proposed care pathway for Long COVID

based on a rapid systematic review of care models for Long COVID - June 2021



## OVERARCHING PRINCIPLES

Patient-centered care


Patient empowerment

Evidence-based care

Integrated & coordinated care

Shared & multidisciplinary care

## Patient Pathway



## OUTCOMES

Quality of life

Patient experience

Provider experience

Sustainable cost



# A proposed care pathway for Long COVID

based on a rapid systematic review of care models for Long COVID - June 2021



## OVERARCHING PRINCIPLES

Patient-centered care


Patient empowerment

Evidence-based care

Integrated & coordinated care

Shared & multidisciplinary care

## Patient Pathway



## OUTCOMES

Quality of life

Patient experience

Provider experience

Sustainable cost

# A proposed care pathway for Long COVID

based on a rapid systematic review of care models for Long COVID - June 2021



## OVERARCHING PRINCIPLES

Patient-centered care


Patient empowerment

Evidence-based care

Integrated & coordinated care

Shared & multidisciplinary care

## Patient Pathway



## OUTCOMES

Quality of life

Patient experience

Provider experience

Sustainable cost

# A proposed care pathway for Long COVID

based on a rapid systematic review of care models for Long COVID - June 2021



## OVERARCHING PRINCIPLES

Patient-centered care


Patient empowerment

Evidence-based care

Integrated & coordinated care

Shared & multidisciplinary care

## Patient Pathway



## OUTCOMES

Quality of life

Patient experience

Provider experience

Sustainable cost

# A proposed care pathway for Long COVID

based on a rapid systematic review of care models for Long COVID - June 2021



## OVERARCHING PRINCIPLES

Patient-centered care


Patient empowerment

Evidence-based care

Integrated & coordinated care

Shared & multidisciplinary care

## Patient Pathway



## OUTCOMES

Quality of life

Patient experience

Provider experience

Sustainable cost

# Discussion

- Rapid review... to living review! Update coming in November
- The implementation of care models from Long COVID is underway in several countries
- Many interfaces, including rehabilitation, lack a detailed description to operationalize the services
- Evidence concerning rehabilitation interventions is building rapidly and this will impact model pathways and trajectories
- There is still unmet needs in the current form of rehab models (e.g. return to work, children)
- New evidence still limited to large countries health systems.
- Real-time and locally contextualized data could be captured from already running clinical initiatives worldwide
- No impact and cost analysis data

# **I am taking history lessons from patient communities...**

**A care model that is safe, adaptable, integrated, equitable, accessible, financially sustainable and most importantly that improves the experience and engagement with care for people with disabilities from Long COVID, post infectious conditions and any other chronic or episodic disabilities.**

# Thank you!

Email: [simon.decary@usherbrooke.ca](mailto:simon.decary@usherbrooke.ca)

Twitter: @SimonDecary

## Prepared by:



Simon Décary, PT, PhD  
Léa Langlois, MSc  
Annie LeBlanc, PhD

Michèle Dugas, MSc  
Becky Skidmore, PhD

Théo Stefan, MSc  
Anne Bhéreur, MD

## For and in close collaboration with:

Alberta Health Services  
Stephanie Hastings, PhD  
Branden Manns, MD, MSc  
Lynora Saxinger, PhD





# COVID LONGUE

CANEVAS D'ÉVALUATION EN PHYSIOTHÉRAPIE



## CONTEXTE DU PROJET



UDS

Université de  
Sherbrooke



**CURE** Clinique universitaire de  
réadaptation de l'Estrie

Membre du réseau d'enseignement de l'Université de Sherbrooke

# NOS OBJECTIFS

1. Guide d'évaluation pour Physiothérapeutes avec clientèle COVID Longue
2. Uniformiser prise en charge de cette clientèle
3. Canevas du HMA, S-O-A-P, Diagramme
4. Récole d'informations complète (drapeaux rouges et jaunes, précautions) et guider la prise de décision incluant référencement



The background is a dark blue gradient with several glowing green virus particles of varying sizes scattered across it. On the right side, there are faint, circular data-like graphics, including a large circular scale with numbers from 80 to 200 and several concentric circles with arrows, suggesting a technical or scientific theme.

# UN CONTINUUM

Début des Sx → COVID

Sx multi systémiques >12 semaines → COVID Longue

- Fatigue
- PEM
- Dysfonction cognitive
- Essoufflement

# POST EXERTIONAL MALAISE (PEM)

1. Exacerbation Sx: Épuisement, Cognition, Neuromusculaire
2. Déclenché 0-48h post effort mineur physique, cognitif ou émotionnel
3. Durée de 24h à 7 jours et +
4. Interférence avec rythme de vie normal



<https://www.health.belgium.be/fr/node/38026>

# COMMENT UTILISER LE CANEVAS?

**Connaître** la présentation clinique, l'évolution des Sx


**Récolter** L'HMA → Informations Subjectives

Utiliser le Diagramme pour:

**Choisir les tests** selon données récoltées

ET du portrait global individuel

**Choisir l'intervention** appropriée



# CONTENU DU TRAVAIL

## 1. Canevas d'évaluation

- HMA, Subjectif, Objectif, Analyse, Plan
- Informations détaillées

## 2. Diagramme = résumé du canevas

- Texte en gras: Tests principaux
- Texte avec étoile: Banque de tests prioritaires

**Subjectif:**

**Sx systémiques**

- Fatigue  Oui  Non,  Physique,  Cognitive
  - Augmenté par : activité  physique
  - Diminué par : \_\_\_\_\_
  - Fatigue mtn VS avant covid : \_\_\_\_\_
  - Qu'est-ce qui arrive quand vous essayez de continuer : \_\_\_\_\_
  - Sx précurseurs fatigue : \_\_\_\_\_
- PEM: Questions de dépistage\*
  - Est-ce qu'il vous est déjà arrivé d'être épuisé après une activité physique?  Oui  Non
- PEM  Oui  Non
  - Déclenchés par effort:  Physique,  Cognitive
  - Délai apparition sx : \_\_\_\_\_
  - Durée du PEM: \_\_\_\_\_
  - Sx qui indiquent PEM : \_\_\_\_\_
- Fièvre  Oui  Non
- Faiblesse  Oui  Non
  - Locale : \_\_\_\_\_
  - Générale: \_\_\_\_\_
- Sommeil  Oui  Non
- Insomnie  Oui  Non
- Sommeil réparateur  Oui  Non
- Autre : \_\_\_\_\_
- Dyspnée  Oui  Non
  - Présente  au repos,  à l'effort
- Toux  Oui  Non
  - Expectorations  Oui  Non Couleur : \_\_\_\_\_

**Objectif:**

Batterie de tests (**core outcome**) recommandés pour tous les pts  
**DePaul, 30sSTS/2mWT, Signes vitaux, Dyspnée, Patron resp, HTO, POTS, ROM QS/QI/axial**

**Symptômes systémiques:**

- **Échelle DePaul\***
- **Fatigue severe/axial\***
- Bilans musculaires
- 5 STS

**Symptômes respiratoires:**

- **Échelle de BORG\***
- 5 STS, 1'Sts, 30s STS\*, 2MWTT\*, 6MWT, Step test 2 min
- **Patron respiratoire\***
- **Mobilité rachis\***
- **Souplesse MS**
- Expansion thoracique
- Toux
- **Signes vitaux (FR, FC, TA, Sa)**
  - Sa : 1'Sts, 2'Step test, 6MWT, diminution de ≥ 5% ou Sa < 90% pour pt sans pathologie pulmonaire connue, ou 88% pour pt avec pathologie connue

**Sx somnifères**

- **Dépistage HTO\*** (TA aux transferts) : **Diminution TAS > 20mmHg ou TAD > 10mmHg vs la base dans les 3min en position debout.** Active stand test: FC et TA mesurées après 5min en DD, puis immédiatement à la position debout, puis à 2, 5 et 10min debout

**Sx respiratoires**


- **Dépistage POTS\*** (FC aux transferts) : **Augmentation soutenue de ≥ 30 bpm vs la base ou ≥ 120 bpm dans les premières 10min en position debout ET Sx orthostatiques.** Active stand test: FC et TA mesurées après 5min en DD, puis immédiatement à la position debout, puis à 2, 5 et 10min debout
- 5 STS, 1'Sts, 30s STS\*, 2MWTT\*, 6MWT, Step test 2 min
- Signes vitaux (FR, FC, TA, Sa)

**Symptômes musculosquelettiques:**

- Examen musculosquelettique (**Examen sommaire QS\* et QI\***)

**Symptômes neurologiques:**

- **Tests de neurodynamique**
- Berg, TUG




# DIAGRAMME DÉCISIONNEL

- Drapeaux rouges:**
- Dir poitrine ou serrement ou aggravation de dir à la poitrine non-investiguée
  - Palpitations cardiaques non-investiguées
  - Désaturation post effort non-investigué
  - COQ qui révèle un haut risque de suicide
  - Sx non-investigués: fièvre, hémoptysie, syncope
- Drapeaux jaunes:**
- PEM récurrents
  - Facteurs psychosociaux
  - Troubles de sommeil

- Histoire de la maladie (HMA) :**
- HMA traditionnelle en physiothérapie.
- Questions spécifiques:
- Date d'infection initiale
  - Liste des sx initiaux + sévérité (EVA)
  - Traitements reçus lors de l'infection initiale
  - Hospitalisation? Si oui, pour combien de temps?
  - Ventilation mécanique?
  - Évolution des sx initiaux (idurée des sx, quels sx ont disparus, lesquels sont restés?)
  - Liste de sx COVID longue + sévérité (EVA)
  - CA + ATCD
  - Résultats tests médicaux passés et à venir
  - Impact AVQ/AVD
  - Travail
  - Loisirs
  - Environnement physique/social

- Précautions:**
- PEM
  - Myocardite ou maladie cardio-vasculaire connue
  - POTS
  - Dysfonction coagulation
  - FC augmentée
  - HTO
  - Confusion

11 sphères



## DRAPEAUX ROUGES

- Dlr poitrine ou serrement ou aggravation de dlr à la poitrine non-investiguée (md/urgence)
- Palpitations cardiaques non-investiguées (md/urgence)
- Désaturation post effort non-investigué ( $\downarrow \geq 5\%$  ou  $Sa < 90\%$  vs  $88\%$ )
- COQ (haut risque de suicide)
- Sx non-investigués: Fièvre, Hémoptysie, Syncope

## DRAPEAUX JAUNES

- PEM récurrents
- Facteurs psychosociaux
- Troubles de sommeil

## PRÉCAUTIONS

- PEM (+ au DePaul)
- Myocardite ou maladie cardio-vasculaire connue (recommandations cardiologue)
- POTS ( $\uparrow \geq 30$  bpm ou  $\geq 120$  bpm, en 10min debout)
- Dysfonction coagulation (souffle court + dlr jambe, signe/sx infarctus, signe/sx TVP)
- FC augmentée (Monitorer FC)
- HTO ( $\downarrow$ TAS  $> 20$ mmHg ou TAD  $> 10$ mmHg en 3min debout)
- Confusion



# HMA: PARTICULARITÉS COVID LONGUE

Date infection initiale

Liste Sx initiaux + Sévérité (EVA)

Traitements reçus

Hospitalisation? Ventilation mécanique?

Évolution des Sx (durée, disparus vs persistants)


Liste Sx actuels + Sévérité, CA, ATCD

Résultats examens médicaux (Bilan sanguin, ECG, Rx pulmonaire, Spirométrie, Échographie, Holter)

Impacts AVQ/AVD, Loisirs, Tolérance

Environnement physique et social

Travail (AT, tentatives RAT)



# SUBJECTIF: EXPLORER LES SYSTÈMES

Multi systémique: 11 sphères à investiguer




# ÉVALUATION SUBJECTIVE

Approfondir selon le HMA

11 sphères: prioriser

Rôle de dépistage vs Dx



# OBJECTIF: TESTER ET MESURER

BANQUES DE TESTS ASSOCIÉS À CHAQUE SYSTÈME

A magnifying glass is positioned on the left side of the slide, with its lens pointing towards the center. The background is a gradient of teal and blue, featuring faint technical diagrams such as circular gauges and arrows. The title 'ÉVALUATION OBJECTIVE' is written in large, white, sans-serif capital letters on the right side.

# ÉVALUATION OBJECTIVE

Adapté au profil du patient

Utiliser raisonnement clinique pour choisir les tests

- Jugement clinique
- Mesure d'évolution vs Comparer aux normes
- Sécuritaire

Reconnaître ses limites : Référer/Collaborer

- Physiothérapeute
- Ergothérapeute
- Médecin
- Pharmacien
- Nutritionniste

# SX SYSTEMIQUES

## EXAMEN SUBJECTIF

Fatigue accablante/disproportionnée

Questions de dépistage PEM

Caractéristiques du PEM

Fièvre

Faiblesse

## EXAMEN OBJECTIF

DePaul

Fatigue severity scale

Bilans musculaires

5x Sit to Stand



# SX RELIÉS AU SOMMEIL

## EXAMEN SUBJECTIF

Insomnie

Sommeil réparateur

## EXAMEN OBJECTIF

Index de sévérité de l'insomnie (ISI)



# SX RESPIRATOIRES

## EXAMEN SUBJECTIF

Dyspnée (repos, effort)

Toux

Expectorations

Difficulté à respirer

Bruit à la respiration

## EXAMEN OBJECTIF

Échelle de BORG

5 STS, 30STS, 2MWT,  
6MWT

Patron respiratoire

Expansion thx


Auscultation

Toux

Signes vitaux (FR, Sa)

Dépistage HTO

ROM Cx, Thx





# SX CARDIO-VASCULAIRES

## EXAMEN SUBJECTIF

Palpitations, Tachycardie

Orthostatisme

Douleur thx

Évanouissement



## EXAMEN OBJECTIF

Signes vitaux (FC, TA, Sa)

5 STS, 30STS, 2MWT, 6MWT

Dépistage POTS:

- Nasa Lean Test

→ Référence médecin si sx inconnus

# SX MUSCULOSQUELETTIQUES

## EXAMEN SUBJECTIF

Douleurs

Diminution mobilité

Faiblesse

## EXAMEN OBJECTIF

Examen musculosquelettique



# SX NEUROLOGIQUES

## EXAMEN SUBJECTIF

Picotements

Engourdissements

Chocs électriques

Sensibilité sensorielle

## EXAMEN OBJECTIF

Examen musculosquelettique

Examen neurologique

Tests neurodynamiques

Examen des NC

VOMS



# SX ORL (YEUX, OREILLES, NEZ, GORGE)

## EXAMEN SUBJECTIF

Changement goût      Étourdissements

Changement odorat      Céphalée

Changement ouïe      Questions NC

Changement vision

## EXAMEN OBJECTIF

VOMS

Examen vestibulaire

Évaluation NC

Examen Cx



# SX COGNITIFS

## EXAMEN SUBJECTIF

Tolérance lecture, écriture

Brouillard mental

Confusion/Désorientation

Trouble concentration

Difficulté multi-tâche


Prise de décision/résolution problème

## EXAMEN OBJECTIF

VOMS

Évaluation des NC

Référence Ergothérapie



# SX ÉMOTIONNELS

## EXAMEN SUBJECTIF

Anxiété

Irritabilité

Sx dépressifs

Gestion émotions



## EXAMEN OBJECTIF

Inventaire dépression de Beck

COQ (idées suicidaires)

→ Plan sécurité et Référencement

# SX GASTRO-INTESTINAUX

## EXAMEN SUBJECTIF

Problèmes de digestion

Problème alimentation



## INTERVENTION

Référence médecin

Référence nutritionniste



# SX REPRODUCTIFS, GÉNITO-URINAIRES, ENDOCRINIENS

## EXAMEN SUBJECTIF

Changements a/n génital

Changements a/n urinaire

Changement a/n cycle menstruel

## EXAMEN OBJECTIF

Évaluation périnéale / Référence RPP

→ Référence médecin





# SECTION ANALYSE ET PLAN

Impression clinique

Tableau: Liste de problèmes et plan de traitement

- Déficiences et modalités principales
- Classé selon système

Objectifs en physiothérapie



# ANALYSE + PLAN DE TRAITEMENT

## Analyse et plan de traitement

Impression clinique :

---

---

---

Liste de problèmes et plan de traitement :

#	Déficiences/limitations/restrictions (priorisation)	Modalités de traitement
	PEM actifs	<input type="checkbox"/> Conseils/Éducation : Identifier PEM, Sx précurseurs <input type="checkbox"/> Intégrer dosage, segmentation, repos, éviter PEM <input type="checkbox"/> Via :
	<input type="checkbox"/> Fatigue/ <input type="checkbox"/> Trouble du sommeil/ Diminution endurance <input type="checkbox"/> Physique ou <input type="checkbox"/> Cognitive	<input type="checkbox"/> Dosage <input type="checkbox"/> Techniques relaxation, <input type="checkbox"/> Hygiène sommeil <input type="checkbox"/> Conseils : _____ <input type="checkbox"/> Via :
	<input type="checkbox"/> Brouillard mental/ <input type="checkbox"/> Trouble concentration Diminution tolérance : <input type="checkbox"/> Lecture, <input type="checkbox"/> Écriture, <input type="checkbox"/> Rapports sociaux, <input type="checkbox"/> Lumière, <input type="checkbox"/> Écrans, <input type="checkbox"/> Bruit	<input type="checkbox"/> Exposition graduelle activité <input type="checkbox"/> Rééducation oculaire <input type="checkbox"/> Coquilles, Bouchons, Cache-yeux, Filtre lumière bleue <input type="checkbox"/> Conseils : _____ <input type="checkbox"/> Via :
	<input type="checkbox"/> Dyspnée/ <input type="checkbox"/> Sensation restriction respiratoire	<input type="checkbox"/> Exercices respiration : _____ <input type="checkbox"/> <u>Inspirométrie</u> <input type="checkbox"/> Via :

# PRISE EN CHARGE


Collaboration avec Ergothérapeute:

Systemique, Sommeil, Cognitif, Sensoriel, Émotif

- Organiser horaire occupationnel
- Gestion d'énergie (marge manœuvre)
- Dosage activités (adaptation tâche, compensations)
- Expositions progressives selon exigences (physiques, cognitives, affectives, sensorielles)
- Conseils hygiène de vie

Reconnaître ses limites: Référer





## CONCLUSION

Maladie multi systémique

Notre rôle: Collecter → Dépister → Partager

Collaboration interdisciplinaire

# RÉFÉRENCES

Diapo 3: Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re'em, Y., ... & Akrami, A. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *Available at SSRN 3820561*.

Diapo 4: Stussman, B., Williams, A., Snow, J., Gavin, A., Scott, R., Nath, A., & Walitt, B. (2020). Characterization of post-exertional malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome. *Frontiers in Neurology, 11*, 1025.

Diapo 8: Rehab-allied-health-practice-considerations-post-covid.pdf.

Diapo 9: Postigo-Martin, P., Cantarero-Villanueva, I., Lista-Paz, A., Castro-Martín, E., Arroyo-Morales, M., & Seco-Calvo, J. (2021). A COVID-19 Rehabilitation Prospective Surveillance Model for Use by Physiotherapists. *Journal of clinical medicine, 10*(8), 1691.

Diapo 10 à 24:

- **Subjectif:**

- Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re'em, Y., Redfield, S., Austin, J. P. et Akrami, A. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine, 38*, 101019. <https://doi.org/10.1016/j.eclinm.2021.101019>
- Bateman L, Bsted AC, Bonilla HF. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management - ClinicalKey. Accessed November 23, 2021. <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0025619621005139?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0025619621005139%3Fshowall%3Dtrue&referrer=https:%2F%2Fpubmed.ncbi.nlm.nih.gov%2F>

- **Objectif:**

- Postigo-Martin P, Cantarero-Villanueva I, Lista-Paz A, Castro-Martín E, Arroyo-Morales M, Seco-Calvo J. A COVID-19 Rehabilitation Prospective Surveillance Model for Use by Physiotherapists. *J Clin Med.* 2021;10(8):1691. doi:10.3390/jcm10081691
- covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742.pdf. Accessed November 23, 2021. <https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742>
- Rehab-allied-health-practice-considerations-post-covid.pdf.